Anti-tumor necrosis factor therapy for sepsis: Still a player?

Critical Care Medicine

Volumn 29, Issue 4, 2001, Pages 905-906

  Dellinger, R P ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anti tumor necrosis factor therapy; Corticosteroids; Recombinant activated protein C; Sepsis; Severe sepsis

Indexed keywords

ACTIVATED PROTEIN C; AFELIMOMAB; CORTICOSTEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; DRUG EFFECT; EDITORIAL; PRIORITY JOURNAL; SEPSIS;

EID: 0035051511     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200104000-00049     Document Type: Editorial

References (7)

1. Randomized, placebo-controlled trial of the antitumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES study
2. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment
3. Clinical trials of mediator-directed therapy in sepsis: What have we learned?
4. Anticytokine therapy: A new era in the treatment of rheumatoid arthritis?
5. Neutralization of TN? by a monoclonal antibody improves survival and reduces organ dysfunction in human sepsis: Results of the MONARCS Trial
6. Effects of the combination of hydrocortisone (HC)-fludro-cortisone (FC) on mortality in septic shock
7. The efficacy and safety of recombinant human activated protein C for the treatment of patients with severe sepsis